Fresenius Medical Care Canada is dedicated to the Canadian Nephrology Community and to providing the superior products and services necessary to achieve the best possible outcomes for Canadian renal disease patients. In October of 2017, Fresenius acquired Canadian distribution rights for Venofer® (Iron Sucrose Injection, USP) and DexIron® (Iron Dextran Injection, USP). This is the start of our vision to build a portfolio of pharmaceutical products that complements our current medical equipment and services used in renal diseases. We will also soon begin to add to our team of high performing individuals that will help to bring the vision to reality. In future years Fresenius hopes to bring products to Canadians in other areas of renal disease with a high unmet medical need.